Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: A single institution experience

Journal of Surgical Oncology

Volumn 109, Issue 5, 2014, Pages 434-439

  Forster, Meghan R ^a   Rashid, Omar M ^b   Perez, Matthew C ^b   Choi, Junsung ^b   Chaudhry, Tariq ^b   Zager, Jonathan S ^b  

^a CAROLINAS MEDICAL CENTER   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

liver metastasis; minimally invasive; percutaneous hepatic perfusion

Indexed keywords

BLOOD CLOTTING FACTOR; CARBOPLATIN; CONTRAST MEDIUM; DOXORUBICIN; FRESH FROZEN PLASMA; GRANULOCYTE COLONY STIMULATING FACTOR; GROWTH FACTOR; IFOSFAMIDE; IPILIMUMAB; MELPHALAN; NORADRENALIN; PACLITAXEL; PHENYLEPHRINE; PROTAMINE SULFATE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TROPONIN; VASOPRESSIN;

ADULT; AGED; ANEMIA; ARTICLE; ASPIRATION CATHETER; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER OF UNKNOWN PRIMARY SITE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CRYOPRECIPITATE; DISEASE COURSE; ERYTHROCYTE CONCENTRATE; EYE TUMOR; FEMALE; FOLLOW UP; HEART VENTRICLE ARRHYTHMIA; HEPARINIZATION; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; INTRAVENOUS CATHETER; LEIOMYOSARCOMA; LIVER METASTASIS; LIVER PERFUSION; LIVER SARCOMA; LUNG DISEASE; MALE; METASTATIC MELANOMA; MIDDLE AGED; MORBIDITY; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERCUTANEOUS HEPATIC PERFUSION; PLASMA TRANSFUSION; PNEUMONIA; PNEUMOTHORAX; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SIDE EFFECT; SURGICAL TECHNIQUE; THROMBOCYTOPENIA; TREATMENT RESPONSE;

LIVER METASTASIS; MINIMALLY INVASIVE; PERCUTANEOUS HEPATIC PERFUSION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DISEASE-FREE SURVIVAL; EYE NEOPLASMS; FEMALE; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LEIOMYOSARCOMA; LIVER NEOPLASMS; MALE; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; SARCOMA; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84897026864     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23501     Document Type: Article

References (20)

1. Adam R, Miller R, Pitombo M, et al.: Two-stage hepatectomy: A planned strategy to treat irresectable liver tumors. Ann Surg 2000; 232: 777-785.
2. Ruers T, Bleichrodt RP,: Treatment of liver metastases, an update on the possibilities and results. Eur J Cancer 2002; 38: 1023-1033.
3. Savier E, Azoulay A, Huguet E, et al.: Percutaneous isolated hepatic perfusion for chemotherapy: A phase 1 study. Arch Surg 2003; 138: 325-332.
4. Kivela T, Eskelin S, Kujala E,: Metastatic uveal melanoma. Int Ophthalmol Clin 2006; 46: 133-149.
5. Woodman SE,: Metastatic uveal melanoma: Biology and emerging treatments. Cancer J 2012; 18: 148-152.
6. Alexander HR, Jr., Libutti SK, Pingpank JF, et al.: Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2003; 9: 6343-6349.
7. Pawlik TM, Zorzi D, Abdalla EK, et al.: Hepatic resection for metastatic melanoma: Distinct patterns of recurrence and prognosis for ocular versus cutaneous disease. Ann Surg Oncol 2006; 13: 712-720.
8. Deneve JL, Choi J, Gonzalez RJ, et al.: Chemosaturation with percutaneous hepatic perfusion for unresectable isolated hepatic metastases from sarcoma. Cardiovasc Intervent Radiol 2012; 35: 1480-1487.
9. Han D, Beasley GM, Tyler DS, et al.: Minimally invasive intra-arterial regional therapy for metastatic melanoma: Isolated limb infusion and percutaneous hepatic perfusion. Expert Opin Drug Metab Toxicol 2011; 7: 1383-1394.
10. Alexander HR, Jr., Butler CC,: Development of isolated hepatic perfusion via the operative and percutaneous techniques for patients with isolated and unresectable liver metastases. Cancer J 2010; 16: 132-141.
11. Grover A, Alexander HR, Jr.:, The past decade of experience with isolated hepatic perfusion. Oncologist 2004; 9: 653-664.
12. Lin G, Lunderquist A, Hagerstrand I, et al.: Postmortem examination of the blood supply and vascular pattern of small liver metastases in man. Surgery 1984; 96: 517-526.
13. Ku Y, Tominaga M, Iwasaki T, et al.: Isolated hepatic perfusion chemotherapy for unresectable malignant hepatic tumors. Int J Clin Oncol 2002; 7: 82-90.
14. Ravikumar TS, Dixon K,: Isolated liver perfusion for liver metastases: Pharmacokinetic advantage ? Surg Oncol Clin N Am 1996; 5: 443-449.
15. Alexander HR, Libutti SK, Bartlett DL, et al.: A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver. Clin Cancer Res 2000; 6: 3062-3070.
16. Beheshti MV, Denny DF, Jr., Glickman MG, et al.: Percutaneous isolated liver perfusion for treatment of hepatic malignancy: Preliminary report. J Vasc Interv Radiol 1992; 3: 453-458.
17. Weinreich DM, Alexander HR, Jr.:, Transarterial perfusion of liver metastases. Semin Oncol 2002; 29: 136-144.
18. Pingpank JF, Libutti SK, Chang R, et al.: Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in patients with unresectable hepatic malignancies. J Clin Oncol 2005; 23: 3465-3474.
19. Pingpank JF, Hughes MS, Faries MB, et al.: A phase III random assignment trial comparing percutaneous hepatic perfusion with melphalan (PHP-mel) to standard of care for patients with hepatic metastases from metastatic ocular or cutaneous melanoma. ASCO Meet Abstr 2010; 28: LBA8512.
20. Miao N, Pingpank JF, Alexander HR, Jr., et al.: Percutaneous hepatic perfusion in patients with metastatic liver cancer: Anesthetic, hemodynamic, and metabolic considerations. Ann Surg Oncol 2008; 15: 815-823.